GHRP-2
Growth-hormone-releasing peptide-2 · Pralmorelin
Overview
GHRP-2 (also known as Pralmorelin) is a synthetic hexapeptide (Ala-D-Lys-Ala-Trp-D-Phe-Lys-NH2, though the exact sequence is sometimes reported with minor variants in the literature) and a GHSR (ghrelin / growth-hormone secretagogue receptor) agonist within the broader GHRP family. GHRP-2 produces robust GH release and was historically approved as a diagnostic agent for evaluating GH-secretory capacity, particularly in Japan where it has been used clinically as Pralmorelin. Compared with Ipamorelin (the GH-selective member of the family), GHRP-2 has somewhat broader receptor activity that also drives cortisol and prolactin release at higher doses, the trade-off being slightly larger GH-release magnitudes at the cost of less-clean receptor selectivity. Lyochem supplies GHRP-2 (Pralmorelin) as a lyophilized powder at ≥99.0% HPLC purity. The hexapeptide synthesis is straightforward, and the analytical packet covers peak-integration HPLC plus mass spec. Two standard fill sizes (5 mg and 10 mg) cover typical research workflows. For research workflows where clean GH-selectivity matters (avoiding cortisol-axis confounders), Ipamorelin is the more appropriate choice; GHRP-2 is preferred when maximum GH-release magnitude is the priority over receptor selectivity.
Who buys this, and why
GH-axis peptides ship to research labs studying somatotropic-pathway pharmacology, IGF-axis signalling, and pulse vs. sustained-elevation GH biology. Buyers qualifying a new source typically request sequence verification on the first lot, the counter-ion form (acetate by default), and stability data at −20 °C. Blends — the CJC-1295 + Ipamorelin co-formulated lot is the canonical example — are co-lyophilised rather than solution-mixed so the ratio is locked at the lyophilisation step.
Primary buyer fit: academic and contract research laboratories.
Specifications
- CAS
- 158861-67-7
- Appearance
- White lyophilized powder
- Purity (HPLC)
- ≥ 99.0%
- Common vial sizes
- 5 mg, 10 mg
- MOQ
- On request
- Lead time
- 10–18 days
- Storage
- -20°C, protect from light
Documentation available on request
- Lot-specific Certificate of Analysis (CoA)
- RP-HPLC chromatogram with peak integration
- ESI-MS identity confirmation (±0.5 Da)
- Sequence verification by LC-MS/MS
- Water content by Karl Fischer
- SDS / MSDS
- Counter-ion analysis (acetate vs TFA)
- Stability at −20 °C across 12 months
- Solubility in BAC water / PBS reconstitution
Regulatory note
Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form, not labelled for human administration, and not supplied to compounding pharmacies — Lyochem's GH-axis lots are scoped to research workflows only. Buyers studying somatotropic pharmacology should specify the counter-ion form (acetate by default) and any pulse-vs-sustained study design notes at quote stage.
Frequently asked questions
How does GHRP-2 differ from Ipamorelin in receptor selectivity?▾
Both peptides are GHSR (ghrelin receptor) agonists, but their selectivity profiles diverge meaningfully. Ipamorelin is highly selective for GHSR over the receptors that regulate cortisol, prolactin, and ACTH release, making it the cleanest GH-selective member of the GHRP family. GHRP-2 has broader activity, producing larger absolute GH-release magnitudes but with measurable secondary effects on cortisol and prolactin axes at higher doses. For research workflows where clean GH-selectivity matters (avoiding cortisol-axis confounders in cellular or in vivo readouts), Ipamorelin is the more appropriate choice; GHRP-2 is preferred when maximum GH-release amplitude is the primary endpoint. Both pair well with CJC-1295 in dual-pathway protocols, though the canonical commercial blend is built around Ipamorelin.
What's the regulatory history of GHRP-2 as Pralmorelin?▾
GHRP-2 was approved in Japan in 2006 under the generic name Pralmorelin (brand: GHRP Kaken) as a diagnostic agent for evaluating growth-hormone-secretory capacity in suspected adult GH deficiency. The approval was based on the molecule's reliable GH-release response in subjects with intact pituitary function and the absence of response in subjects with GH deficiency. The diagnostic-use indication remains the only approved indication for GHRP-2 in any major jurisdiction; the molecule is widely used as a research tool for GHSR pathway studies but lacks therapeutic-use approval. Buyers in Japan can reference the local clinical-use documentation; buyers elsewhere should treat GHRP-2 as a research-use compound.